| Name | Title | Contact Details |
|---|---|---|
Aymii Couzelis |
Chief Information Officer | Profile |
Vividion Therapeutics, Inc. is a biotechnology company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets. The company is advancing a broad, diversified pipeline of multiple, selective small molecule therapeutics for highly sought-after disease-causing target proteins in oncology and immunology. The company`s cutting-edge platform was spun out of the labs of Vividion`s scientific founders, a team of experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA.
Ensuring safe and secure management of reproductive specimens world wide. Tank failures happen. Specimens don’t have to be lost because of that. We can help.
We are a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets.
We are a clinical stage development and licensing biotechnology company focused on leveraging our Pfenex Expression Technology™ platform to develop and improve protein therapies for unmet patient needs.
Elektrofi is a biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs. Its breakthrough formulation platform enables stabilized, highly concentrated formulations for subcutaneous administration. The company is using this technology to transform therapies that are administered intravenously, and to enhance injectable products by reducing the volume and frequency of dosing. Elektrofi partners with pharmaceutical companies to jointly develop patient-friendly delivery solutions. Headquartered in Boston, the company`s founding team of MIT engineers and scientists are shaping the future of biologics delivery.